Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation
about
Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer modelAn adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expressionX-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivoBikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatmentPhase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.Die and let live: harnessing BikDD to combat breast cancer stem cells.Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells.Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells.A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccinesSynergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.MiR-199b-5p targets HER2 in breast cancer cells.MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation.Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen speciesA Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models.
P2860
Q33575434-35AFACAB-8D12-441C-BEF1-86C560B55235Q33699124-91643375-A60F-44DB-BFFE-F358A8DC1A74Q33798772-744C309C-A0F7-4B4F-8187-11457F38DD6FQ33829405-500D3C4C-2CE4-4837-AD67-D5A50CB105CDQ34214918-9ADC7578-D4D9-4BE0-B736-44BD1401D41CQ34504365-1831BB89-8092-41C9-887C-4D497E4CBC8BQ34581860-32EB99EA-66D1-49AA-A2B2-89EFEBF5BC51Q34632169-9C347837-9EB0-4BDB-AF7B-5F2D987A2E16Q35836070-F152F66D-8C5B-45D2-93C5-CF84F3EF494DQ35846880-66704D8A-CDA9-4BE6-B196-68DAD31DFE7BQ35913109-FCED640D-D54A-4B47-9DFA-489BA5E971B4Q36245312-87F7B44D-190F-4940-8290-DCB40711F590Q36412836-59128082-7001-4276-B45B-FD0DBA017237Q36516589-0C654F3A-F02D-4B70-B462-47A4C19FCCB9Q37036297-BE22612F-4EC8-4420-8956-6DE1DD78D45FQ37072265-1DDFAB6C-741C-4282-8D9C-AA2F48CD8FEFQ37163577-E135C8DE-0629-41D8-8025-F5E29A62E448Q37173925-10E07E20-1B10-442A-A702-3073AA55DCC9Q37227994-132500B3-59F7-401B-8641-1BE0A0C570BBQ37268127-6E5DB72D-8D13-4095-AA22-B36B9054500BQ37460333-137DE79A-801A-41DC-AA1C-88B005263C4CQ37589245-D5477154-347D-43D6-AF1C-E637F94428E5Q37621597-AABB3FEC-1939-40DD-8370-004519723135Q37690880-A8384949-BB11-471D-9221-441E2A190AA3Q38812867-D94C8995-B874-4BFB-A0E5-7C37A5DB3876Q39136014-6B0A2FC9-1CE9-4672-92A9-999451ECBE7BQ39214783-8CCA0C1B-0818-4632-AAE4-60C3DBAF1341Q39411394-60EAC20C-EE30-403C-BF1B-D6D01AB8214BQ39528587-A34B678A-1F3B-4E3D-A2D3-31B4C5938EA6Q39733170-B4AF287F-C064-4881-86AA-752A38EEEF6FQ40492036-C193F5A1-1686-4A4A-B064-43720572FA8BQ51110603-4C40ABB3-C65F-4ED9-AE65-1AEB50609935
P2860
Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Lapatinib resistance in HCT116 ...... ERBB receptor kinase mutation
@en
type
label
Lapatinib resistance in HCT116 ...... ERBB receptor kinase mutation
@en
prefLabel
Lapatinib resistance in HCT116 ...... ERBB receptor kinase mutation
@en
P2093
P2860
P356
P1476
Lapatinib resistance in HCT116 ...... ERBB receptor kinase mutation
@en
P2093
Aditi Pandya Martin
Adly Yacoub
Anna Miller
Clint Mitchell
Margaret A Park
Michael P Hagan
Mohammed Rahmani
Paul B Fisher
Steven Grant
P2860
P304
P356
10.1124/MOL.108.047365
P50
P577
2008-06-10T00:00:00Z